Unknown

Dataset Information

0

Serum metabolomic profiling of prostate cancer risk in the prostate, lung, colorectal, and ovarian cancer screening trial.


ABSTRACT:

Background

Two recent metabolomic analyses found serum lipid, energy, and other metabolites related to aggressive prostate cancer risk up to 20 years prior to diagnosis.

Methods

We conducted a serum metabolomic investigation of prostate cancer risk in the Prostate, Lung, Colorectal, and Ovarian Cancer Screening Trial that included annual serum total prostate-specific antigen measurement and digital rectal examination. This nested study included 380 cases diagnosed post-screening and 380 controls individually matched to cases on age, race, study centre, and blood-collection date (median time to diagnosis, 10 years (range 4.4-17 years)). Sera were analysed on a high-resolution accurate mass platform of ultrahigh-performance liquid and gas chromatography/mass spectroscopy that identified 695 known metabolites. Logistic regression conditioned on the matching factors estimated odds ratios (OR) and 95% confidence intervals of risk associated with an 80th percentile increase in the log-metabolite signal.

Results

Twenty-seven metabolites were associated with prostate cancer at P<0.05. Pyroglutamine, gamma-glutamylphenylalanine, phenylpyruvate, N-acetylcitrulline, and stearoylcarnitine showed the strongest metabolite-risk signals (ORs=0.53, 0.51, 0.46, 0.58, and 1.74, respectively; 0.001?P?0.006). Findings were similar for aggressive disease (peptide chemical class, P=0.03). None of the P-values were below the threshold of Bonferroni correction, however.

Conclusions

A unique metabolomic profile associated with post-screening prostate cancer is identified that differs from that in a previously studied, unscreened population.

SUBMITTER: Huang J 

PROVIDER: S-EPMC5117796 | biostudies-literature | 2016 Oct

REPOSITORIES: biostudies-literature

altmetric image

Publications

Serum metabolomic profiling of prostate cancer risk in the prostate, lung, colorectal, and ovarian cancer screening trial.

Huang Jiaqi J   Mondul Alison M AM   Weinstein Stephanie J SJ   Koutros Stella S   Derkach Andriy A   Karoly Edward E   Sampson Joshua N JN   Moore Steven C SC   Berndt Sonja I SI   Albanes Demetrius D  

British journal of cancer 20160927 9


<h4>Background</h4>Two recent metabolomic analyses found serum lipid, energy, and other metabolites related to aggressive prostate cancer risk up to 20 years prior to diagnosis.<h4>Methods</h4>We conducted a serum metabolomic investigation of prostate cancer risk in the Prostate, Lung, Colorectal, and Ovarian Cancer Screening Trial that included annual serum total prostate-specific antigen measurement and digital rectal examination. This nested study included 380 cases diagnosed post-screening a  ...[more]

Similar Datasets

| S-EPMC2873186 | biostudies-literature
| S-EPMC3582194 | biostudies-literature
| S-EPMC3131220 | biostudies-literature
| S-EPMC4254357 | biostudies-literature
| S-EPMC4289432 | biostudies-literature
| S-EPMC5557093 | biostudies-other
| S-EPMC3818308 | biostudies-literature
| S-EPMC3168068 | biostudies-literature
| S-EPMC3185107 | biostudies-literature
| S-EPMC4272608 | biostudies-literature